WO2005094384A3 - Methods and compositions for treatment of ion imbalances - Google Patents

Methods and compositions for treatment of ion imbalances Download PDF

Info

Publication number
WO2005094384A3
WO2005094384A3 PCT/US2005/011010 US2005011010W WO2005094384A3 WO 2005094384 A3 WO2005094384 A3 WO 2005094384A3 US 2005011010 W US2005011010 W US 2005011010W WO 2005094384 A3 WO2005094384 A3 WO 2005094384A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treatment
ion imbalances
sodium
Prior art date
Application number
PCT/US2005/011010
Other languages
French (fr)
Other versions
WO2005094384A2 (en
Inventor
Robert Alpern
Jerry M Buysse
Han Ting Chang
Dominique Charmot
Michael James Cope
John Fordtran
Gerrit Klaerner
Original Assignee
Ilypsa Inc
Robert Alpern
Jerry M Buysse
Han Ting Chang
Dominique Charmot
Michael James Cope
John Fordtran
Gerrit Klaerner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35054544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005094384(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority to AU2005228696A priority Critical patent/AU2005228696B2/en
Priority to GB0621244A priority patent/GB2430368B/en
Application filed by Ilypsa Inc, Robert Alpern, Jerry M Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner filed Critical Ilypsa Inc
Priority to DE112005000725.1T priority patent/DE112005000725B4/en
Priority to KR1020067022590A priority patent/KR101199608B1/en
Priority to EP05747062A priority patent/EP1732524B1/en
Priority to CA2557999A priority patent/CA2557999C/en
Priority to JP2007506295A priority patent/JP5000480B2/en
Priority to BRPI0509331A priority patent/BRPI0509331B8/en
Publication of WO2005094384A2 publication Critical patent/WO2005094384A2/en
Publication of WO2005094384A3 publication Critical patent/WO2005094384A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium­binding polymers and pharmaceutical compositions thereof Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
PCT/US2005/011010 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances WO2005094384A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0509331A BRPI0509331B8 (en) 2004-03-30 2005-03-30 use of a sodium binding composition
JP2007506295A JP5000480B2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion balance abnormalities
CA2557999A CA2557999C (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
EP05747062A EP1732524B1 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
GB0621244A GB2430368B (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
AU2005228696A AU2005228696B2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
DE112005000725.1T DE112005000725B4 (en) 2004-03-30 2005-03-30 Methods and compositions for treating ion imbalances
KR1020067022590A KR101199608B1 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/813,872 2004-03-30
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 2004-03-30
US10/814,749 2004-03-30
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
US10/965,274 2004-10-13

Publications (2)

Publication Number Publication Date
WO2005094384A2 WO2005094384A2 (en) 2005-10-13
WO2005094384A3 true WO2005094384A3 (en) 2006-01-26

Family

ID=35054544

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2005/011010 WO2005094384A2 (en) 2004-03-30 2005-03-30 Methods and compositions for treatment of ion imbalances
PCT/US2005/010978 WO2005097081A1 (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof
PCT/US2005/010747 WO2005097072A1 (en) 2004-03-30 2005-03-30 Ion binding compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2005/010978 WO2005097081A1 (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof
PCT/US2005/010747 WO2005097072A1 (en) 2004-03-30 2005-03-30 Ion binding compositions

Country Status (12)

Country Link
US (14) US7776319B2 (en)
EP (3) EP1732523B9 (en)
JP (3) JP4974882B2 (en)
KR (3) KR101228233B1 (en)
AU (3) AU2005231424B2 (en)
BR (3) BRPI0509331B8 (en)
CA (3) CA2557999C (en)
DE (1) DE112005000730B4 (en)
GB (3) GB2430624B (en)
MX (1) MXPA06011270A (en)
PL (1) PL1732523T3 (en)
WO (3) WO2005094384A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018651A1 (en) 2003-08-26 2005-03-03 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
CA2557999C (en) * 2004-03-30 2013-11-12 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances
CA2806465C (en) * 2004-03-30 2016-05-24 Relypsa Ion binding polymers and uses thereof
KR20080059265A (en) * 2005-09-30 2008-06-26 일립사, 인코포레이티드 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
DE112006002617T5 (en) * 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Process for the preparation of core-shell composites or core-shell composites with crosslinked shells and resulting core-shell composites
CN100398112C (en) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 Medicine for treating hyperphosphatemia and its preparing method
RS52706B (en) * 2006-10-06 2013-08-30 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
EP2108661A1 (en) * 2006-12-26 2009-10-14 Chisso Corporation Metal salt of crosslinked cellulose derivative
JP5277965B2 (en) * 2006-12-26 2013-08-28 Ｊｎｃ株式会社 Sodium absorption inhibitor, potassium absorption inhibitor and phosphorus absorption inhibitor, and prophylactic, therapeutic and food containing the same
CA2686414A1 (en) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
CA2697803A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
JP5294681B2 (en) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 Substrate processing apparatus and substrate transport method
AU2013204879B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
DK2365988T4 (en) * 2008-08-22 2019-10-07 Vifor Int Ltd CROSS-EXTENDED CATION EXCHANGE POLYMERS, COMPOSITIONS AND APPLICATIONS FOR TREATMENT OF HYPERCALIA
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
PT2550305T (en) 2010-03-20 2018-04-20 Relypsa Inc Continuous process for preparing polyfluoroacrylate particles
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
ES2709004T3 (en) 2011-02-11 2019-04-12 Zs Pharma Inc Use of a zirconium silicate for the treatment of hyperkalemia
US9453092B2 (en) 2011-06-27 2016-09-27 Relypsa, Inc. Process for converting a polymeric ester to a polymeric acid
EP2723708B1 (en) 2011-06-27 2019-09-04 Relypsa, Inc. Fluorination of acrylate esters and derivatives
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
CA2878832A1 (en) * 2012-07-11 2014-01-16 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
IN2015DN01369A (en) * 2012-07-19 2015-07-03 Relypsa Inc
JP6115973B2 (en) 2012-08-09 2017-04-19 パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー Method for drying polymer material
BR112015007749A2 (en) 2012-10-08 2017-07-04 Relypsa Inc methods for treating hypertension, hyperkalaemia, and chronic kidney disease.
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
WO2014066407A1 (en) 2012-10-22 2014-05-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia
HUE034836T2 (en) 2013-06-05 2018-03-28 Tricida Inc Proton-binding polymers for oral administration
JP5740523B1 (en) * 2013-12-11 2015-06-24 株式会社 資生堂 Early diagnosis marker of renal failure
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (en) * 2014-09-30 2019-02-13 積水化成品工業株式会社 Hollow resin particles and method for producing the same
US11311571B2 (en) 2014-12-10 2022-04-26 Tricida, Inc. Proton-binding polymers for oral administration
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (en) 2015-12-23 2017-06-23 Rjw Pharma Llc PROCEDURE FOR THE SYNTHESIS OF PATIROMER
RU2018142943A (en) 2016-05-06 2020-06-08 Трисида, Инк. COMPOSITIONS FOR TREATING ACID-BASIC EQUILIBRIUM DISORDERS
JP2018125951A (en) * 2017-01-31 2018-08-09 日本電産株式会社 Motor and air blowing device with the same
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
JP7365631B2 (en) * 2019-09-02 2023-10-20 国立大学法人福井大学 Core-shell type polymer fine particles having phosphonic acid or phosphonic acid ester structure, particle dispersion, molded body, and method for producing the fine particles
CN113244339B (en) * 2021-06-04 2021-09-24 南京厚生药业有限公司 Cholestyramine powder for hyperlipidemia and preparation method thereof
WO2023088111A1 (en) * 2021-11-17 2023-05-25 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
WO2024035944A1 (en) * 2022-08-12 2024-02-15 University Of Kansas Extraction of critical minerals using polyanions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141927A (en) * 1990-07-04 1992-08-25 Marcin Krotkiewski Antihypertensive preparation comprising an alginate and vitamin D

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) * 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (en) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4380590A (en) 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
SE8003805L (en) 1980-05-21 1981-11-22 Haessle Ab A PHARMACEUTICAL PREPARATION WITH IMPROVED EMISSION PROPERTY
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (en) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING PEARL POLYMERISATS OF UNIFORM PARTICLE SIZE
DE3149136A1 (en) * 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart DEVICE FOR REGULATING THE FUEL-AIR RATIO IN INTERNAL COMBUSTION ENGINES
JPS6090243A (en) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Small spherical crosslinked monoallylamine polymer and its preparation
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4675140A (en) 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (en) 1986-06-16 1988-02-16 Prodotti Formenti Srl PHARMACEUTICAL COMPOSITIONS WITH SEQUESTRANT ACTIVITY OF BILE ACIDS CONTAINING COLESTYRAMINE AS THE ACTIVE INGREDIENT, AND PROCEDURE TO PREPARE THEM
JPS63218713A (en) * 1987-02-17 1988-09-12 Daikin Ind Ltd Alpha-fluoroacrylic acid polymer and use thereof
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (en) 1988-06-30 1991-09-27 Cortial NOVEL EXTENDED RELEASE PHARMACEUTICAL FORM BASED ON AN ACTIVE RESIN-PRINCIPLE COMPLEX
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (en) 1989-09-01 1991-03-07 Bayer Ag METHOD FOR PRODUCING (ALPHA) -FLUOROACRYLIC ACID DERIVATIVES
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
ES2080549T3 (en) * 1992-03-28 1996-02-01 Hoechst Ag MEDICINES BASED ON POLYHYDROXYMETHYLENE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND USE.
JPH08500386A (en) 1992-08-20 1996-01-16 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー Crosslinked polymer ammonium salt
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5718920A (en) * 1993-11-25 1998-02-17 Salternate B.V. Particles for binding monovalent cations
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (en) 1996-06-11 2007-02-21 株式会社大塚製薬工場 Guanidino compound reducing agent and moisture and potassium ion adsorbent
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
EP0907666A1 (en) 1996-06-27 1999-04-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (en) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc Life prolongation ratio improver for nephritis patient
US6475510B1 (en) 1997-12-19 2002-11-05 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
CA2348885A1 (en) * 1998-11-06 2000-05-18 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
JP2002534374A (en) * 1999-01-07 2002-10-15 エラン コーポレーシヨン ピーエルシー Multiparticulate oral dosage form
US6558665B1 (en) 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
AU780873B2 (en) 2000-01-14 2005-04-21 Otsuka Pharmaceutical Factory, Inc. Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
FR2812632B1 (en) 2000-08-07 2003-03-07 Solvay PROCESS FOR THE SYNTHESIS OF FLUOROORGANIC COMPOUNDS
EP2324861A1 (en) 2000-11-20 2011-05-25 Sorbent Therapeutics, Inc. In vivo use of water absorbent polymers
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
JP2004149525A (en) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd Potassium ion adsorbent, method for producing the same, and therapeutic agent for hyperkalemia
ES2396679T3 (en) * 2003-02-25 2013-02-25 Dupont Nutrition Biosciences Aps A simulated mobile bed system
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
CA2557999C (en) 2004-03-30 2013-11-12 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
DE112006002617T5 (en) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Process for the preparation of core-shell composites or core-shell composites with crosslinked shells and resulting core-shell composites
KR20080059265A (en) 2005-09-30 2008-06-26 일립사, 인코포레이티드 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141927A (en) * 1990-07-04 1992-08-25 Marcin Krotkiewski Antihypertensive preparation comprising an alginate and vitamin D

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOUSTAFINE R.I. ET AL: "Characteristics of interpolyelectrolyte complexes for Eudragit E 100 with sodium alginate.", INTERNATIONAL JOURNAL OF PHARMACEUTICS., vol. 294, no. 1-2, 27 April 2005 (2005-04-27), pages 113 - 120, XP004825465 *

Also Published As

Publication number Publication date
US7776319B2 (en) 2010-08-17
BRPI0509366A (en) 2007-09-04
WO2005097081A1 (en) 2005-10-20
GB2430368A (en) 2007-03-28
US8475780B2 (en) 2013-07-02
US20110033505A1 (en) 2011-02-10
DE112005000730T5 (en) 2008-07-03
KR20060135045A (en) 2006-12-28
JP4964122B2 (en) 2012-06-27
BRPI0509366B8 (en) 2021-05-25
KR101228233B1 (en) 2013-01-31
EP1732523B1 (en) 2010-03-17
AU2005231383B2 (en) 2010-06-10
KR20070007168A (en) 2007-01-12
CA2557999A1 (en) 2005-10-13
CA2558029C (en) 2013-05-07
BRPI0509331B1 (en) 2018-11-27
EP1732524B1 (en) 2012-08-22
GB2430367A (en) 2007-03-28
GB2430367B (en) 2009-08-05
US20140286891A1 (en) 2014-09-25
US8409561B2 (en) 2013-04-02
US20160082039A1 (en) 2016-03-24
JP2007531758A (en) 2007-11-08
MXPA06011270A (en) 2007-03-08
US20200085856A1 (en) 2020-03-19
GB2430624B (en) 2009-08-05
US8282913B2 (en) 2012-10-09
KR20060135044A (en) 2006-12-28
GB0621242D0 (en) 2006-12-13
US20090148533A1 (en) 2009-06-11
EP1732516B1 (en) 2009-12-30
GB0621244D0 (en) 2006-12-13
WO2005094384A2 (en) 2005-10-13
GB2430368B (en) 2009-08-26
EP1732524A2 (en) 2006-12-20
US20080233073A1 (en) 2008-09-25
EP1732523A4 (en) 2007-06-06
BRPI0509365B1 (en) 2018-06-12
EP1732523A1 (en) 2006-12-20
AU2005228696A1 (en) 2005-10-13
US8216560B2 (en) 2012-07-10
GB0621241D0 (en) 2006-12-13
US20060024265A1 (en) 2006-02-02
EP1732524A4 (en) 2007-09-19
US20080241093A1 (en) 2008-10-02
JP4974882B2 (en) 2012-07-11
US10485821B2 (en) 2019-11-26
CA2557999C (en) 2013-11-12
US20130272991A1 (en) 2013-10-17
PL1732523T3 (en) 2010-08-31
DE112005000730B4 (en) 2017-12-21
JP2007531726A (en) 2007-11-08
US8445014B2 (en) 2013-05-21
BRPI0509365A (en) 2007-09-04
US8778324B2 (en) 2014-07-15
AU2005231424A1 (en) 2005-10-20
WO2005097072A1 (en) 2005-10-20
BRPI0509331A (en) 2007-09-04
CA2557848A1 (en) 2005-10-20
EP1732516A1 (en) 2006-12-20
BRPI0509366B1 (en) 2018-07-24
US20080241092A1 (en) 2008-10-02
BRPI0509331B8 (en) 2021-05-25
US20130272992A1 (en) 2013-10-17
US20110206631A1 (en) 2011-08-25
BRPI0509365B8 (en) 2021-05-25
US20160317572A1 (en) 2016-11-03
US8889115B2 (en) 2014-11-18
JP5000480B2 (en) 2012-08-15
CA2557848C (en) 2013-12-10
AU2005231424B2 (en) 2010-06-17
US20130272990A1 (en) 2013-10-17
GB2430624A (en) 2007-04-04
KR101199608B1 (en) 2012-11-08
CA2558029A1 (en) 2005-10-20
KR101153035B1 (en) 2012-06-11
EP1732523B9 (en) 2010-06-02
US8287847B2 (en) 2012-10-16
AU2005228696B2 (en) 2010-06-24
JP2007531774A (en) 2007-11-08
AU2005231383A1 (en) 2005-10-20
EP1732516A4 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
WO2005094384A3 (en) Methods and compositions for treatment of ion imbalances
WO2005092039A3 (en) Crosslinked amine polymers
WO2006043984A3 (en) Crosslinked amine polymers
EP1745792A4 (en) Adsorbent for oral administration, preventive or remedy for kidney disease and preventive or remedy for liver disease
WO2007078516A3 (en) Medical devices having multiple charged layers
WO2009086206A3 (en) Compositions and methods for joining non-conjoined lumens
GB2446076A (en) Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007149999A3 (en) Compositions and methods for joining non-conjoined lumens
EP1745793A4 (en) Adsorbent for oral administration, therapeutic or preventive agent for kidney disease, and therapeutic or preventive agent for liver disease
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007038801A3 (en) Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
EP2184059A3 (en) Ion binding polymers and uses thereof
PL368572A1 (en) Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
WO2009004094A3 (en) Compounds and methods for the treatment of renal disease
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
WO2004103291A3 (en) Extended release compositions of proton pump inhibitor
WO2009012400A3 (en) Orally administered peptides to improve or prevent hepatic fibrosis
WO2007039909A3 (en) Compositions and methods for treatment of renal failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2557999

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005747062

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005228696

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005228696

Country of ref document: AU

Date of ref document: 20050330

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011210

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2005228696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580010568.0

Country of ref document: CN

Ref document number: 2007506295

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1120050007251

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 0621244.3

Country of ref document: GB

Ref document number: 0621244

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 1020067022590

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005747062

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067022590

Country of ref document: KR

RET De translation (de og part 6b)

Ref document number: 112005000725

Country of ref document: DE

Date of ref document: 20070503

Kind code of ref document: P

ENP Entry into the national phase

Ref document number: PI0509331

Country of ref document: BR